The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa

被引:12
|
作者
Jamieson, Lise [1 ,2 ]
Gomez, Gabriela B. [3 ]
Rebe, Kevin [4 ]
Ben Brown [4 ]
Subedar, Hasina [5 ]
Jenkins, Sarah [6 ]
Shoko, Natsai [7 ]
Bekker, Linda-Gail [8 ]
Johnson, Leigh F. [9 ]
Meyer-Rath, Gesine [1 ,2 ,10 ]
机构
[1] Hlth Econ & Epidemiol Res Off HE2RO, Johannesburg, South Africa
[2] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Johannesburg, South Africa
[3] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London, England
[4] ANOVA Hlth Inst, Cape Town, South Africa
[5] Natl Dept Hlth, Pretoria, South Africa
[6] Clinton Hlth Access Initiat, Philadelphia, PA USA
[7] Clinton Hlth Access Initiat, Pretoria, South Africa
[8] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa
[9] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa
[10] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA
基金
美国国家卫生研究院;
关键词
cost; cost-effectiveness analysis; high-risk populations; preexposure prophylaxis; South Africa; HETEROSEXUAL MEN; PREVENTION; INFECTION; WOMEN; TRANSMISSION; COUPLES;
D O I
10.1097/QAD.0000000000002486
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: We explored the impact and cost-effectiveness of preexposure prophylaxis (PrEP) provision to different populations in South Africa, with and without effective self-selection by individuals at highest risk of contracting HIV (through concurrent partnerships and/or commercial sex). Design and methods: We used a previously developed HIV transmission model to analyse the epidemiological impact of PrEP provision to adolescents, young adults, pregnant women, female sex workers (FSWs) and (MSM), and data from South African PrEP programmes to estimate the cost and cost-effectiveness of PrEP (cost in 2019 USD per HIV infection averted over 20 years, 2019, 38). PrEP uptake followed data from early implementation sites, scaled-up linearly over 3 years, with target coverage set to 18% for adolescents, young adults and pregnant women, 30% for FSW and 54% for MSM. Results: The annual cost of PrEP provision ranges between $75 and $134 per person. PrEP provision adolescents and young adults, regardless of risk behaviour, will each avert 3.2--4.8% of HIV infections over 20 years; provision to high-risk individuals only has similar impact at lower total cost. The incremental cost per HIV infection averted is lower in high-risk vs. all-risk sub-populations within female adolescents ($507 vs. $4537), male adolescents ($2108 vs. $5637), young women ($1592 vs. $10 323) and young men ($2605 vs. $7715), becoming cost saving within 20 years for high-risk adolescents, young women, MSM and FSWs. Conclusion: PrEP is an expensive prevention intervention but uptake by those at the highest risk of HIV infection will make it more cost-effective, and cost-saving after 14-18 years.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 50 条
  • [41] Cost-effectiveness of pre-exposure prophylaxis for HIV: a review
    Schackman, Bruce R.
    Eggman, Ashley A.
    CURRENT OPINION IN HIV AND AIDS, 2012, 7 (06) : 587 - 592
  • [42] Cost-effectiveness of HIV post-exposure prophylaxis in France
    Herida, Magid
    Larsen, Christine
    Lot, Florence
    Laporte, Anne
    Desenclos, Jean-Claude
    Hamers, Francoise F.
    AIDS, 2006, 20 (13) : 1753 - 1761
  • [43] Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda
    Pitter, Christian
    Kahn, James G.
    Marseille, Elliot
    Lule, John R.
    McFarland, Deborah A.
    Ekwaru, John Paul
    Bunnell, Rebecca
    Coutinho, Alex
    Mermin, Jonathan
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 44 (03) : 336 - 343
  • [44] Cost-Effectiveness of Introducing the SILCS Diaphragm in South Africa
    Lepine, Aurelia
    Nundy, Neeti
    Kilbourne-Brook, Maggie
    Siapka, Mariana
    Terris-Prestholt, Fern
    PLOS ONE, 2015, 10 (08):
  • [45] Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency
    Francke, Jordan A.
    Penazzato, Martina
    Hou, Taige
    Abrams, Elaine J.
    MacLean, Rachel L.
    Myer, Landon
    Walensky, Rochelle P.
    Leroy, Valeriane
    Weinstein, Milton C.
    Parker, Robert A.
    Freedberg, Kenneth A.
    Ciaranello, Andrea
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (09): : 1319 - 1328
  • [46] Shortened Tuberculosis Treatment for People with HIV in South Africa A Model-based Evaluation and Cost-effectiveness Analysis
    Reddy, Krishna P.
    Horsburgh, C. Robert
    Wood, Robin
    Fields, Naomi F.
    Girouard, Michael P.
    Costantini, Sydney
    Hou, Taige
    Freedberg, Kenneth A.
    Walensky, Rochelle P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (02) : 202 - 211
  • [47] Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study
    van Vliet, Marjolein M.
    Hendrickson, Cheryl
    Nichols, Brooke E.
    Boucher, Charles A. B.
    Peters, Remco P. H.
    van de Vijver, David A. M. C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 (12)
  • [48] Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa
    Davey, Dvora L. Joseph
    Bekker, Linda-Gail
    Gomba, Yolanda
    Coates, Thomas
    Myer, Landon
    Johnson, Leigh F.
    AIDS, 2019, 33 (08) : 1391 - 1395
  • [49] Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa
    Sinanovic, E
    Floyd, K
    Dudley, L
    Azevedo, V
    Grant, R
    Maher, D
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2003, 7 (09) : S56 - S62
  • [50] Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in South Africa
    Girdwood, Sarah J.
    Crompton, Thomas
    Sharma, Monisha
    Dorward, Jienchi
    Garrett, Nigel
    Drain, Paul K.
    Stevens, Wendy
    Nichols, Brooke E.
    ECLINICALMEDICINE, 2020, 28